Birgit Wilding
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
Journal: Expert review of anticancer therapy
Published: February 05, 2026
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Journal: Cancer discovery
Published: March 12, 2024
Chemoenzymatic one-pot reaction from carboxylic acid to nitrile via oxime.
Journal: Catalysis science & technology
Published: September 17, 2021
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Journal: Nature cancer
Published: July 27, 2021
Kinetic Analysis and Probing with Substrate Analogues of the Reaction Pathway of the Nitrile Reductase QueF from Escherichia coli.
Journal: The Journal of biological chemistry
Published: July 06, 2016
The Nitrile-Forming Enzyme 7-Cyano-7-Deazaguanine Synthase from Geobacillus kaustophilus: A Reverse Nitrilase?
Journal: Chembiochem : a European journal of chemical biology
Published: July 05, 2015
An investigation of nitrile transforming enzymes in the chemo-enzymatic synthesis of the taxol sidechain.
Journal: Organic & biomolecular chemistry
Published: June 25, 2015
Targeting the substrate binding site of E. coli nitrile reductase QueF by modeling, substrate and enzyme engineering.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: January 16, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026